Targeting this metabolic vulnerability with the potent and selective ASCT2 inhibitor V9302 effectively suppressed AKT/mTOR signaling, induced apoptosis, and inhibited tumor growth in preclinical models of SS. The gene discussed is AKT1; the disease is synovial sarcoma.